OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
degeneration, showing a 46% reduction in macular lesion growth at 12 months for medium and high doses versus control and no therapy-related serious adverse events across Phase 1 and 2. An interesting aspect of the update is that OCU410 uses a gene-agnostic modifier gene therapy approach, aiming to address dry AMD regardless of the specific underlying mutation. We will now examine how this gene-agnostic efficacy signal in dry AMD could influence Ocugen's existing investment narrative and risk profile. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource. Ocugen Investment Narrative Recap To own Ocugen today, you need to believe its gene agnostic platform can turn positive clinical data into approved therapies before cash constraints bi
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]TheStreet.com
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGlobeNewswire
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 4/20/26 - Form PRER14A
- 4/17/26 - Form PRE
- 4/14/26 - Form SCHEDULE
- OCGN's page on the SEC website